血必净在慢性阻塞性肺疾病急性加重期治疗中的作用研究  

Effects of Xuebijing on Patients with Acute Exacerbation Chronic Obstructive Pulmonary Disease

作　　者：陈余清[1] 宫蓓蕾[1] 张永[1] 许启霞[1] 

机构地区：[1]蚌埠医学院第一附属医院呼吸内科,安徽呼吸系病临床基础省级实验室,安徽省蚌埠市233000

出　　处：《中国全科医学》2011年第5期550-553,共4页Chinese General Practice

基　　金：天津市科委科技创新专项基金(06F22DSH00403)

摘　　要：目的探讨血必净在慢性阻塞性肺疾病急性加重期(AECOPD)治疗中的作用及其机制。方法 60例AECOPD患者随机分为常规治疗组和干预治疗组各30例,后者在常规治疗组治疗基础上加血必净注射液100 ml静脉滴注,1次/d,连用7 d;两组于治疗前及治疗后3、7 d检测外周血单核细胞核因子κB(NF-κB)DNA结合活性、炎性标志物水平、动脉血气(ABG)。结果两组患者治疗前NF-κB DNA结合活性比较,差异无统计学意义(P>0.05);两组患者治疗后7 d NF-κB DNA结合活性比较,差异有统计学意义(P<0.05);两组患者治疗后7d肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)水平比较,差异均有统计学意义(P<0.05);干预治疗组患者NF-κB DNA结合活性与TNF-α水平在治疗前及治疗后3 d、7 d均呈正相关(r值分别为0.514,0.405,0.431,P<0.05);与CRP水平亦均呈正相关(r值分别为0.402,0.369,0.384,P<0.05);常规治疗组治疗后有效率为60.0%,干预治疗组为83.3%,两组有效率比较,差异有统计学意义(P<0.05)。结论血必净对AECOPD具有一定治疗作用,可能与其对NF-κB活性的调节有关。Objective To investigate the effects of Xuebijing on patients with acute exacerbation chronic obstructive pulmonary disease（AECOPD） and to elucidate the possible mechanisms involved.Methods Sixty patients with AECOPD were divided randomly into routine therapy group（n=30） and Xuebijing therapy group（n=30）.Xuebijing therapy group were treated with Xuebijing injection（100 ml,once a day） for 7 consecutive days besides routine therapies.The activations of nuclear factor-κB（NF-κB） in human monotypes,the concentrations of tumour necrosis factor（TNF-α） and C-reactive protein（CRP）and arterial blood gas in blood serum were detected at 3 d and 7 d before and after treatment.Results There was no statistical difference on the activations of NF-κB between two groups before treatment（P0.05）,but the statistical difference was found at d7 after treatment（P0.05）.The concentrations of tumour necrosis factor and C-reactive protein between the two groups showed statistical difference at 7d after treatment.There were obvious positive correlations between the activations of NF-κB and the levels of TNF-α or CRP 3 d and 7 d before and after treatment（r=0.514,0.405,0.431 or 0.402,0.369,0.384 respectively,P0.05）.Compared with the routine therapy group（effective rate being 60.0%）,the effective rate of Xuebijing therapy group were higher（83.3%）,the difference was significant（P0.05）.Conclusion Treatment with Xuebijing shows a certain therapeutic effect in patients with AECOPD,and the down-regulative effects on the activations of NF-κB may be the possible mechanism involved.

关 键 词：肺疾病 慢性阻塞性 血必净 药物疗法 

分 类 号：R563.8[医药卫生—呼吸系统]